SEPOY.net
No Result
View All Result
Friday, July 18, 2025
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

Research shows benefit of dapagliflozin for heart failure patients regardless of ejection fraction

Nicholas by Nicholas
August 29, 2022
in Health
0

Dapagliflozin reduces the risks of death and cardiovascular events in patients with heart failure regardless of ejection fraction, according to late-breaking research presented in a Hot Line session today at ESC Congress 2022.

READ ALSO

From chemistry to life: Building synthetic cells with metabolism

Specially engineered antibody delivers RNA therapy to treatment-resistant tumors

This pre-specified patient-level meta-analysis combined the DAPA-HF and DELIVER trials of the SGLT2 inhibitor dapagliflozin in patients with heart failure. DAPA-HF enrolled patients with reduced ejection fraction (40% or less) and DELIVER enrolled patients with mildly reduced and preserved ejection fraction (above 40%). Both trials randomly allocated participants to dapagliflozin 10 mg once daily or placebo.

The first aim of this analysis was to examine the effect of dapagliflozin on a number of secondary outcomes that each trial alone was not powered to examine. The second aim was to examine if dapagliflozin was effective across the entire range of ejection fraction, since the EMPEROR-Preserved trial previously suggested that the effect of empagliflozin, another SGLT2 inhibitor, may be attenuated in patients with higher ejection fraction.

A total of 11,007 patients were randomised to dapagliflozin or placebo in the two trials. Survival analysis was used to examine the effect of dapagliflozin on death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite of death from cardiovascular causes, myocardial infarction, or stroke (major adverse cardiovascular events; MACE).

The average age of participants was 69 years and 35% were women. The median follow up was 1.8 years. Dapagliflozin reduced the risk of death from cardiovascular causes by 14% (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.76-0.97; p=0.01), death from any cause by 10% (HR 0.90; 95% CI 0.82-0.99; p=0.03), total hospital admissions for heart failure by 29% (relative risk [RR] 0.71; 95% CI 0.65-0.78; p<0.001) and MACE by 11% (HR 0.90; 95% CI 0.81-1.00; p=0.045). There was no evidence that the effect of dapagliflozin differed by ejection fraction for any of the outcomes.

Our findings confirm that all patients with heart failure, regardless of ejection fraction, may benefit from dapagliflozin in addition to any other heart failure therapy they are receiving.”


Pardeep Jhund, Study Author, Professor University of Glasgow, UK

Source:

European Society of Cardiology (ESC)

Tags: CardiologyHeartHeart FailureHospitalPlaceboResearch

Related Posts

From chemistry to life: Building synthetic cells with metabolism
Health

From chemistry to life: Building synthetic cells with metabolism

July 17, 2025
Specially engineered antibody delivers RNA therapy to treatment-resistant tumors
Health

Specially engineered antibody delivers RNA therapy to treatment-resistant tumors

July 17, 2025
How can super-resolution technology help study neurotransmission?
Health

How can super-resolution technology help study neurotransmission?

July 17, 2025
Vaccinated women face fewer cervical cancer risks
Health

Vaccinated women face fewer cervical cancer risks

July 17, 2025
Chemotherapy may trigger inflammatory response that fuels bladder cancer resistance
Health

Chemotherapy may trigger inflammatory response that fuels bladder cancer resistance

July 17, 2025
New study tracks how living in an agrihood impacts resident health
Health

New study tracks how living in an agrihood impacts resident health

July 16, 2025
Next Post

After fish kills: Environment Minister Lemke insists on stopping the expansion of the Oder

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: hello@sepoy.net

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • Assistentenprogramm of Oz gebührenfrei bastet and cats 120 freie Spins vortragen bloß Eintragung
  • Were there Coin Learn 100 percent free revolves and you can coin backlinks to have today? July 11, 2025
  • Wheel from Fortune Big Top casino slot Harbors Play Free Wheel out of Fortune Casino slot games

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net